NTLA

insider transactions

Intellia Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

+64.3K

150.0K buy · 85.7K sell

Net value · 365d

$605.3K

$1.4M in · $797.2K out

Sentiment · 365d

Net buying

64% buying · 36% selling

Open-market trades · 365d

150.0K buy · 85.7K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 11, 26

Muna Bhanji

Director

$0

5.3K sh

Own +13%
Grant·A
Jun 9, 26

Frank Verwiel

Director

$0

13.3K sh

Own New
Grant·A
Jun 9, 26

Frank Verwiel

Director

$0

9.2K sh

Own +35%
Grant·A
Jun 9, 26

Georgia Keresty

Director

$0

13.3K sh

Own New
Grant·A
Jun 9, 26

Georgia Keresty

Director

$0

9.2K sh

Own +29%
Grant·A
Jun 9, 26

Brian Goff

Director

$0

13.3K sh

Own New
Grant·A
Jun 9, 26

Brian Goff

Director

$0

9.2K sh

Own +39%
Grant·A
Jun 9, 26

Jesse Goodman

Director

$0

13.3K sh

Own New
Grant·A
Jun 9, 26

Jesse Goodman

Director

$0

9.2K sh

Own +38%
Grant·A
Jun 9, 26

Fred E Cohen

Director

$0

13.3K sh

Own New
Grant·A
Jun 9, 26

Fred E Cohen

Director

$0

9.2K sh

Own +4%
Grant·A
Jun 9, 26

William J Chase

Director

$0

13.3K sh

Own New
Grant·A
Jun 9, 26

William J Chase

Director

$0

9.2K sh

Own +7%
Grant·A
Jun 9, 26

Muna Bhanji

Director

$0

13.3K sh

Own New
Grant·A
Jun 9, 26

Muna Bhanji

Director

$0

9.2K sh

Own +34%
Grant·A
May 27, 26

Muna Bhanji

Director

$0

4.3K sh

Own New
Grant·A
May 27, 26

Muna Bhanji

Director

$0

2.9K sh

Own +12%
Grant·A
May 27, 26

Fred E Cohen

Director

$0

20.6K sh

Own New
Grant·A
May 27, 26

Fred E Cohen

Director

$0

5.1K sh

Own +31%
Grant·A
Apr 15, 26

William J Chase

Director

$20.3K

408 sh · $49.79

Own +1%
Sell·S
Mar 2, 26

Eliana Clark

EVP, Chief Technical Officer

$8.4K

607 sh · $13.78

Own -1%
Sell·S
Mar 2, 26

James Basta

EVP, General Counsel

$16.7K

1.2K sh · $13.78

Own -1%
Grant·A
Mar 1, 26

John M Leonard KEY

President and CEO

$0

225.4K sh

Own New
Grant·A
Mar 1, 26

John M Leonard KEY

President and CEO

$0

156.4K sh

Own +15%
Grant·A
Mar 1, 26

David Lebwohl

EVP, Chief Medical Officer

$0

14.2K sh

Own New
Grant·A
Mar 1, 26

David Lebwohl

EVP, Chief Medical Officer

$0

9.9K sh

Own +8%
Grant·A
Mar 1, 26

Birgit C Schultes

EVP, Chief Scientific Officer

$0

56.0K sh

Own New
Grant·A
Mar 1, 26

Birgit C Schultes

EVP, Chief Scientific Officer

$0

39.2K sh

Own +40%
Grant·A
Mar 1, 26

Edward J Dulac III KEY

EVP, Chief Financial Officer

$0

87.5K sh

Own New
Grant·A
Mar 1, 26

Edward J Dulac III KEY

EVP, Chief Financial Officer

$0

61.3K sh

Own +61%
Grant·A
Mar 1, 26

Dube Michael P

VP, Chief Accounting Officer

$0

17.2K sh

Own +33%
Grant·A
Mar 1, 26

Eliana Clark

EVP, Chief Technical Officer

$0

10.5K sh

Own New
Grant·A
Mar 1, 26

Eliana Clark

EVP, Chief Technical Officer

$0

7.4K sh

Own +8%
Grant·A
Mar 1, 26

James Basta

EVP, General Counsel

$0

65.8K sh

Own New
Grant·A
Mar 1, 26

James Basta

EVP, General Counsel

$0

46.1K sh

Own +41%
Grant·A
Jan 15, 26

William J Chase

Director

$20.8K

213 sh · $97.44

Own +1%
Sell·S
Jan 5, 26

John M Leonard KEY

President and CEO

$314.5K

34.1K sh · $9.21

Own -3%
Sell·S
Jan 5, 26

Birgit C Schultes

EVP, Chief Scientific Officer

$78.4K

8.5K sh · $9.21

Own -8%
Sell·S
Jan 5, 26

David Lebwohl

EVP, Chief Medical Officer

$109.6K

11.9K sh · $9.21

Own -9%
Sell·S
Jan 5, 26

Edward J Dulac III KEY

EVP, Chief Financial Officer

$58.8K

6.4K sh · $9.21

Own -6%
Sell·S
Jan 5, 26

Dube Michael P

VP, Chief Accounting Officer

$27.5K

3.0K sh · $9.21

Own -5%
Buy·P
Jan 5, 26

Fred E Cohen

Director

$1.4M

150.0K sh · $9.35

Own +261%
Sell·S
Jan 5, 26

Eliana Clark

EVP, Chief Technical Officer

$87.6K

9.5K sh · $9.21

Own -10%
Sell·S
Jan 5, 26

James Basta

EVP, General Counsel

$95.8K

10.4K sh · $9.21

Own -9%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 11, 2026	Muna Bhanji	Director	Grant A	5.3K	+13%	—	$0
Jun 9, 2026	Frank Verwiel	Director	Grant A	13.3K	New	—	$0
Jun 9, 2026	Frank Verwiel	Director	Grant A	9.2K	+35%	—	$0
Jun 9, 2026	Georgia Keresty	Director	Grant A	13.3K	New	—	$0
Jun 9, 2026	Georgia Keresty	Director	Grant A	9.2K	+29%	—	$0
Jun 9, 2026	Brian Goff	Director	Grant A	13.3K	New	—	$0
Jun 9, 2026	Brian Goff	Director	Grant A	9.2K	+39%	—	$0
Jun 9, 2026	Jesse Goodman	Director	Grant A	13.3K	New	—	$0
Jun 9, 2026	Jesse Goodman	Director	Grant A	9.2K	+38%	—	$0
Jun 9, 2026	Fred E Cohen	Director	Grant A	13.3K	New	—	$0
Jun 9, 2026	Fred E Cohen	Director	Grant A	9.2K	+4%	—	$0
Jun 9, 2026	William J Chase	Director	Grant A	13.3K	New	—	$0
Jun 9, 2026	William J Chase	Director	Grant A	9.2K	+7%	—	$0
Jun 9, 2026	Muna Bhanji	Director	Grant A	13.3K	New	—	$0
Jun 9, 2026	Muna Bhanji	Director	Grant A	9.2K	+34%	—	$0
May 27, 2026	Muna Bhanji	Director	Grant A	4.3K	New	—	$0
May 27, 2026	Muna Bhanji	Director	Grant A	2.9K	+12%	—	$0
May 27, 2026	Fred E Cohen	Director	Grant A	20.6K	New	—	$0
May 27, 2026	Fred E Cohen	Director	Grant A	5.1K	+31%	—	$0
Apr 15, 2026	William J Chase	Director	Grant A	408	+1%	$49.79	$20.3K
Mar 2, 2026	Eliana Clark	EVP, Chief Technical Officer	Sell S	607	-1%	$13.78	$8.4K
Mar 2, 2026	James Basta	EVP, General Counsel	Sell S	1.2K	-1%	$13.78	$16.7K
Mar 1, 2026	John M Leonard KEY	President and CEO	Grant A	225.4K	New	—	$0
Mar 1, 2026	John M Leonard KEY	President and CEO	Grant A	156.4K	+15%	—	$0
Mar 1, 2026	David Lebwohl	EVP, Chief Medical Officer	Grant A	14.2K	New	—	$0
Mar 1, 2026	David Lebwohl	EVP, Chief Medical Officer	Grant A	9.9K	+8%	—	$0
Mar 1, 2026	Birgit C Schultes	EVP, Chief Scientific Officer	Grant A	56.0K	New	—	$0
Mar 1, 2026	Birgit C Schultes	EVP, Chief Scientific Officer	Grant A	39.2K	+40%	—	$0
Mar 1, 2026	Edward J Dulac III KEY	EVP, Chief Financial Officer	Grant A	87.5K	New	—	$0
Mar 1, 2026	Edward J Dulac III KEY	EVP, Chief Financial Officer	Grant A	61.3K	+61%	—	$0
Mar 1, 2026	Dube Michael P	VP, Chief Accounting Officer	Grant A	17.2K	+33%	—	$0
Mar 1, 2026	Eliana Clark	EVP, Chief Technical Officer	Grant A	10.5K	New	—	$0
Mar 1, 2026	Eliana Clark	EVP, Chief Technical Officer	Grant A	7.4K	+8%	—	$0
Mar 1, 2026	James Basta	EVP, General Counsel	Grant A	65.8K	New	—	$0
Mar 1, 2026	James Basta	EVP, General Counsel	Grant A	46.1K	+41%	—	$0
Jan 15, 2026	William J Chase	Director	Grant A	213	+1%	$97.44	$20.8K
Jan 5, 2026	John M Leonard KEY	President and CEO	Sell S	34.1K	-3%	$9.21	$314.5K
Jan 5, 2026	Birgit C Schultes	EVP, Chief Scientific Officer	Sell S	8.5K	-8%	$9.21	$78.4K
Jan 5, 2026	David Lebwohl	EVP, Chief Medical Officer	Sell S	11.9K	-9%	$9.21	$109.6K
Jan 5, 2026	Edward J Dulac III KEY	EVP, Chief Financial Officer	Sell S	6.4K	-6%	$9.21	$58.8K
Jan 5, 2026	Dube Michael P	VP, Chief Accounting Officer	Sell S	3.0K	-5%	$9.21	$27.5K
Jan 5, 2026	Fred E Cohen	Director	Buy P	150.0K	+261%	$9.35	$1.4M
Jan 5, 2026	Eliana Clark	EVP, Chief Technical Officer	Sell S	9.5K	-10%	$9.21	$87.6K
Jan 5, 2026	James Basta	EVP, General Counsel	Sell S	10.4K	-9%	$9.21	$95.8K

About NTLA insider trading

This page tracks insider transactions for Intellia Therapeutics, Inc. (NTLA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.